Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;17(1):17-27.
doi: 10.22037/ghfbb.v17i1.2899.

Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy

Benjamin M Mac Curtain  1 , Luke O'Brien  1 , Omar El Sherif  2 , Aidan Mc Cormack  2 , Emer Carolan  3 , John D Ryan  3 , Donal O'Shea  4 , Tom K Gallagher  1   2
Affiliations

Biguanides and glucagon like peptide 1 receptor agonists in the amelioration of post liver transplant weight gain; a scoping review of the mechanism of action, safety and efficacy

Benjamin M Mac Curtain et al. Gastroenterol Hepatol Bed Bench. 2024.

Abstract

Weight gain post-liver transplant can lead to adverse patient outcomes in the post-transplant period. Pharmacotherapy and other measures can be utilised to reduce the burden and occurrence of weight gain in this population. We explored the mechanism of action, safety, and efficacy of these medications, specifically GLP-1 receptor agonists and metformin, focusing on liver transplant patients. This scoping review was conducted in line with the scoping review structure as outlined by the PRISMA guidelines. Metformin and GLP-1 receptor agonists have been observed to be safe and effective in liver transplant patients. Experimental models have found liver-centric weight loss mechanisms in this drug cohort. There is a paucity of evidence about the use of antihyperglycemics in a post-transplant population for weight loss purposes. However, some small studies have shown strong safety and efficacy data. The evidence in relation to using these medications in patients with metabolic syndrome for weight loss warrants further study in a transplant population.

Keywords: Body weight; Liver transplant; Non-alcoholic steatohepatitis (NASH)..

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest for authors of this article.

Figures

Figure 1
Figure 1
PRISMA chart for studies relating to mechanism of action
Figure 2
Figure 2
PRISMA chart for studies relating to safety and efficacy
See this image and copyright information in PMC

References

    1. Beckmann S, Denhaerynck K, Stampf S, Saigi-Morgui N, Binet I, Koller M, et al. New-onset obesity after liver transplantation—outcomes and risk factors: the Swiss Transplant Cohort Study. Transpl Int. 2018;31:1254–67. - PubMed
    1. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int. 2005;18:461–6. - PubMed
    1. Jeong HW, Jung KW, Kim SO, Kwon HM, Moon YJ, Jun IG, et al. Early postoperative weight gain is associated with increased risk of graft failure in living donor liver transplant recipients. Sci Rep. 2019;9:20096. - PMC - PubMed
    1. Lattanzi B, D'Ambrosio D, Tavano D, Pitoni D, Mennini G, Ginanni Corradini S, et al. Weight gain and De Novo metabolic disorders after liver transplantation. Nutrients. 2019;11:3015. - PMC - PubMed
    1. Vida Perez L, Montero Alvarez JL, Poyato Gonzalez A, Briceño Delgado J, Costan Rodero G, Fraga Rivas E, et al. Prevalence and predictors of metabolic syndrome after liver transplantation. Transplant Proc. 2016;48:2519–24. - PubMed

Publication types

LinkOut - more resources